Clinical trial · Observational
Transabdominal Gastric Contrast Ultrasound
Application Value of Transabdominal Gastric Contrast Ultrasound in the Diagnosis and Staging Evaluation of Gastric Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the clinical data of patients diagnosed with gastric cancer who were ready for surgery were examined by contrast-enhanced ultrasonography and gastric-enhanced CT before surgery. Based on the results of postoperative pathological examinations, the diagnostic accuracy of gastric filling contrast-enhanced ultrasonography and gastric contrast-enhanced CT in different stages of gastric cancer was compared and analyzed. Provide better guidance for follow-up clinical practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Transabdominal Gastric Contrast Ultrasound | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gastric contrast ultrasound | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Experimental group
- description
- Patients with gastric cancer underwent contrast-enhanced CT scan and gastric filling ultrasound, respectively.
- interventionNames
- Diagnostic Test: gastric contrast ultrasound
Primary outcomes (1)
- measure
- Sensitivity, specificity and accuracy of gastric contrast ultrasound in judging gastric cancer staging.
- timeFrame
- one month after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age: 18\~80 years old, male or female; 2. Diagnosed with gastric cancer by histology or cytology; 3. No distant multiple metastasis; 4. ECOG score 0-2; 5. Heart, lung, liver and kidney function can tolerate surgery; 6. Patients and their families can understand and be willing to participate in this clinical study, and sign the informed consent. Exclusion Criteria: 1. Previous history of malignant tumor or recent diagnosis combined with other malignant tumors; 2. Patients with gastrointestinal perforation, gastrointestinal bleeding, etc. requiring emergency surgery; 3. Patients with previous gastroduodenal surgery; 4. Preoperative neoadjuvant therapy; 5. Patients and their families refuse surgical treatment; 6. ASA grade ≥ IV and/or ECOG performance status score \> 2; 7. Patients with severe liver and kidney function, cardiopulmonary function, coagulation dysfunction or combined with serious underlying diseases who cannot tolerate surgery; 8. Have a history of serious mental illness; 9. Pregnant or lactating women; 10. Patients with other clinical and laboratory conditions considered by the researchers should not participate in this trial.
References
Publications (0)
Data not yet available